New CCO to accelerate precision medicine and diagnostics growth

PrecisionLife, a leading innovator in precision medicine for complex chronic diseases, is excited to announce the appointment of Bill Keating as its new Chief Commercial Officer (CCO) for Diagnostics and Healthcare. With over two decades of expertise in corporate and business development across the healthcare and diagnostics sectors, Bill will spearhead the commercialisation of PrecisionLife’s pioneering Mechanostic® tests, designed to predict, prevent, and manage chronic diseases on a global scale.

Bill’s career includes senior roles at industry giants such as Philips Healthcare, Zephyr AI, and Foundation Medicine, where he successfully led the adoption of breakthrough diagnostic solutions. His strategic vision and leadership will be crucial in advancing PrecisionLife’s next-generation diagnostic tools, which aim to transform the management of chronic diseases affecting billions of patients worldwide.

"I’m incredibly excited to join PrecisionLife at this critical juncture," said Bill Keating. "The company’s platform is truly unique, offering scalable insights into complex diseases that have long eluded conventional medicine. PrecisionLife is at the forefront of a new era in healthcare, where predicting and preventing chronic diseases is not just a possibility but a reality. I look forward to driving the growth and global impact of our precision medicine solutions."

Steve Gardner, CEO of PrecisionLife, expressed his enthusiasm about Bill’s appointment: "Bill brings invaluable experience in scaling high-impact healthcare companies, making him the ideal leader to guide our commercial strategy. As we expand our reach and collaborate with healthcare systems worldwide, his expertise will be essential in bringing our groundbreaking solutions to market and improving patient outcomes."

PrecisionLife’s innovative diagnostic tools utilise proprietary insights to offer non-invasive, genotypic testing that pinpoints the genetic causes of complex diseases. The company’s personalised approach supports targeted treatment, optimising patient care while reducing healthcare inefficiencies. Bill Keating’s leadership will ensure the rapid adoption of these transformative solutions as they redefine chronic disease management.

More information online